Mattheus Cornelis De Wilde;Patrick Joseph Gerardus Hendrikus Kamphuis;Robert Johan Joseph Hageman
发明人:
Robert Johan Joseph Hageman,Mattheus Cornelis De Wilde,Patrick Joseph Gerardus Hendrikus Kamphuis
申请号：
US12142981
公开号：
US08497238B2
申请日:
2008.06.20
申请国别(地区):
US
年份:
2013
代理人:
摘要：
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises:a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA)；b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine； andc) a mineral fraction comprising at least one of manganese and molybdene,the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
